Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
182
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 49 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 18 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADHEROZA (DIN 02550989) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02550989 | approvedsource: Marketed | health-canada-dpd |
| Sep 14, 2026 | Ropeginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as BESREMI (DIN 02569728) under ATC L03AB15 ROPEGINTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02569728 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Pimicotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PIMJETMI (DIN 02569035) under ATC L01X OTHER ANTINEOPLASTIC AGENTS. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02562502 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Mosunetuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUNSUMIO SC (DIN 02567377) under ATC L01FX25 MOSUNETUZUMAB. Indications are not published in the Drug Product… | DIN02567377 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 5, 2026 | Mosunetuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUNSUMIO (DIN 02565226) under ATC L01FX25 MOSUNETUZUMAB. Indications are not published in the Drug Product Database —… | DIN02565226 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Sevabertinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as HYRNUO (DIN 02563444) under ATC L01EH06 SEVABERTINIB. Indications are not published in the Drug Product Database —… | DIN02563444 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ENZALUTAMIDE (DIN 02562677) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02562677 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP ENZALUTAMIDE (DIN 02515229) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02515229 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 02562855) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN02562855 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Nivolumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OPDIVO SC (DIN 02557320) under ATC L01FF01 NIVOLUMAB. Indications are not published in the Drug Product Database —… | DIN02557320 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Pirtobrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAYPIRCA (DIN 02562014) under ATC L01EL05 PIRTOBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02562014 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | Quizartinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VANFLYTA (DIN 02558351) under ATC L01EX11 QUIZARTINIB. Indications are not published in the Drug Product Database —… | DIN02558351 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02558971) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 4, 2026 | Selpercatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as RETEVMO (DIN 02565676) under ATC L01EX22 SELPERCATINIB. Indications are not published in the Drug Product Database —… | DIN02565676 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 31, 2026 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02562499 | approvedsource: Marketed | health-canada-dpd |
| Jul 31, 2026 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562480) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02562480 | approvedsource: Marketed | health-canada-dpd |
| Jul 31, 2026 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562472) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02562472 | approvedsource: Marketed | health-canada-dpd |
| Jul 31, 2026 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562464) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02562464 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Amivantamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYBREVANT SC (DIN 02569175) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database… | DIN02569175 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Amivantamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYBREVANT SC (DIN 02569167) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database… | DIN02569167 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Amivantamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYBREVANT SC (DIN 02569159) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database… | DIN02569159 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Amivantamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYBREVANT SC (DIN 02569140) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database… | DIN02569140 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02560224) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02560224 | approvedsource: Marketed | health-canada-dpd |
| Jul 24, 2026 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02560216) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02560216 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 16, 2026 | Mosunetuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUNSUMIO SC (DIN 02567369) under ATC L01FX25 MOSUNETUZUMAB. Indications are not published in the Drug Product… | DIN02567369 | approvedsource: Marketed | health-canada-dpd |
| Jun 3, 2026 | Zolbetuximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VYLOY (DIN 02563916) under ATC L01FX31 ZOLBETUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02563916 | approvedsource: Marketed | health-canada-dpd |
| Jun 2, 2026 | Daunorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DAUNORUBICIN INJECTABLE SOLUTION (DIN 02501481) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the… | DIN02501481 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 1, 2026 | Tislelizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVIMBRA (DIN 02564009) under ATC L01FF09 TISLELIZUMAB. Indications are not published in the Drug Product Database —… | DIN02564009 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 30, 2026 | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-ENZALUTAMIDE (DIN 02558424) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02558424 | approvedsource: Marketed | health-canada-dpd |
| Mar 30, 2026 | Quizartinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VANFLYTA (DIN 02558378) under ATC L01EX11 QUIZARTINIB. Indications are not published in the Drug Product Database —… | DIN02558378 | approvedsource: Marketed | health-canada-dpd |
| Mar 30, 2026 | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-ENZALUTAMIDE (DIN 02494736) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product… | DIN02494736 | approvedsource: Marketed | health-canada-dpd |
| Mar 5, 2026 | Pembrolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as KEYTRUDA SC (DIN 02565382) under ATC L01FF02 PEMBROLIZUMAB. Indications are not published in the Drug Product… | DIN02565382 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 26, 2026 | Toripalimab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LOQTORZI (DIN 02562219) under ATC L01FF13 TORIPALIMAB. Indications are not published in the Drug Product Database —… | DIN02562219 | approvedsource: Marketed | health-canada-dpd |
| Jan 9, 2026 | Mirvetuximab Soravtansine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELAHERE (DIN 02560771) under ATC L01FX26 MIRVETUXIMAB SORAVTANSINE. Indications are not published in the Drug Product… | DIN02560771 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 22, 2025 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP NINTEDANIB (DIN 02550849) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02550849 | approvedsource: Marketed | health-canada-dpd |
| Dec 22, 2025 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP NINTEDANIB (DIN 02540762) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02540762 | approvedsource: Marketed | health-canada-dpd |
| Dec 22, 2025 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-NINTEDANIB (DIN 02526905) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02526905 | approvedsource: Marketed | health-canada-dpd |
| Dec 22, 2025 | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-NINTEDANIB (DIN 02526891) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02526891 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 28, 2025 | Pirtobrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAYPIRCA (DIN 02562006) under ATC L01EL05 PIRTOBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02562006 | approvedsource: Marketed | health-canada-dpd |
| Nov 28, 2025 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-METHOTREXATE TABLETS (DIN 02561956) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02561956 | approvedsource: Marketed | health-canada-dpd |
| Nov 26, 2025 | Treosulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TREOSULFAN FOR INJECTION (DIN 02560585) under ATC L01AB02 TREOSULFAN. Indications are not published in the Drug… | DIN02560585 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 14, 2025 | Sotorasib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUMAKRAS (DIN 02552655) under ATC L01XX73 SOTORASIB. Indications are not published in the Drug Product Database — see… | DIN02552655 | approvedsource: Marketed | health-canada-dpd |
| Oct 1, 2025 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRZ-ABIRATERONE (DIN 02540460) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02540460 | approvedsource: Marketed | health-canada-dpd |
| Oct 1, 2025 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRZ-ABIRATERONE (DIN 02540452) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02540452 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 30, 2025 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-SUNITINIB (DIN 02552892) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02552892 | approvedsource: Marketed | health-canada-dpd |
| Sep 30, 2025 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-SUNITINIB (DIN 02552906) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02552906 | approvedsource: Marketed | health-canada-dpd |
| Sep 30, 2025 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-SUNITINIB (DIN 02539284) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02539284 | approvedsource: Marketed | health-canada-dpd |
| Sep 29, 2025 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP ANASTROZOLE TABLETS (DIN 02540584) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug… | DIN02540584 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2025 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as FILRA (DIN 02556545) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see… | DIN02556545 | approvedsource: Marketed | health-canada-dpd |